Thus, inhibition of GFD11 and GDF8 with sotatercept might contribute to the beneficial effects in PAH, but the pleiotropic roles of these ligands and Activin A in normal homeostasis warrant careful consideration and thorough investigation of the impact of their blockade. Here, MSTN is linked to pulmonary arterial hypertension.